PM360: COVID-19’s Long-Lasting Impact on Clinical Trials

June 16, 2020

With COVID-19 impacting the conduct of clinical trials, a lot of discussion has been around what changes have allowed trials to continue recruitment. Protocol amendments and the use of technology are just a couple examples of trial aspects that have been drastically impacted by the pandemic, and are expected to see many implemented changes remain.

Read the full article here to learn more about how oncology CROs are uncovering solutions to make trials available to patients now and into the future amid current challenges.

A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study

In cancer drug development, monotherapies often lose ground when tumors adapt. This is especially true for KRASmutant non–small cell lung cancers ...

Read more +

Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking

Despite decades of investment in oncology drug development, the translational pipeline from preclinical models to clinical success remains ...

Read more +

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.